Texas Permanent School Fund lessened its holdings in shares of Mylan (NASDAQ:MYL) by 1.5% in the fourth quarter, according to the company in its most recent filing with the Securities Exchange Commission. The institutional investor owned 146,399 shares of the company’s stock after selling 2,221 shares during the quarter. Texas Permanent School Fund’s holdings in Mylan were worth $6,194,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. Clear Harbor Asset Management LLC increased its position in Mylan by 25.3% in the 4th quarter. Clear Harbor Asset Management LLC now owns 13,920 shares of the company’s stock valued at $589,000 after acquiring an additional 2,810 shares during the period. James Investment Research Inc. increased its position in shares of Mylan by 26.6% during the 4th quarter. James Investment Research Inc. now owns 10,345 shares of the company’s stock valued at $438,000 after purchasing an additional 2,175 shares during the period. Kirr Marbach Co. LLC IN acquired a new position in shares of Mylan during the 4th quarter valued at $7,500,000. Lingohr Partner Asset Management GmbH boosted its position in shares of Mylan by 5.0% in the fourth quarter. Lingohr Partner Asset Management GmbH now owns 22,979 shares of the company’s stock worth $972,000 after buying an additional 1,100 shares during the period. Finally, State of Alaska Department of Revenue boosted its position in shares of Mylan by 106.3% in the fourth quarter. State of Alaska Department of Revenue now owns 61,092 shares of the company’s stock worth $2,583,000 after buying an additional 31,480 shares during the period. Hedge funds and other institutional investors own 75.00% of the company’s stock.
In other Mylan news, CEO Heather M. Bresch sold 75,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $45.00, for a total transaction of $3,375,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.69% of the stock is currently owned by corporate insiders.
Mylan (NASDAQ:MYL) opened at $39.28 on Friday. The company has a market capitalization of $21,060.00, a P/E ratio of 23.66, a PEG ratio of 1.06 and a beta of 1.35. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05. Mylan has a 1-year low of $29.39 and a 1-year high of $47.82.
Several analysts have recently commented on MYL shares. Mizuho reaffirmed a “buy” rating and issued a $37.00 target price on shares of Mylan in a research report on Tuesday, October 24th. Zacks Investment Research cut Mylan from a “buy” rating to a “hold” rating in a research report on Wednesday, November 8th. Cantor Fitzgerald set a $41.00 price objective on Mylan and gave the company a “hold” rating in a research report on Tuesday, December 26th. UBS Group set a $46.00 price target on Mylan and gave the stock a “buy” rating in a research report on Monday, December 4th. Finally, Susquehanna Bancshares reaffirmed a “positive” rating and issued a $55.00 price target (up previously from $47.00) on shares of Mylan in a research report on Thursday, January 25th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $44.65.
COPYRIGHT VIOLATION WARNING: “Texas Permanent School Fund Lowers Holdings in Mylan (MYL)” was posted by Week Herald and is the property of of Week Herald. If you are accessing this story on another site, it was illegally copied and republished in violation of international copyright law. The correct version of this story can be accessed at https://weekherald.com/2018/02/11/mylan-myl-holdings-reduced-by-texas-permanent-school-fund.html.
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News Ratings for Mylan Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mylan and related companies with MarketBeat.com’s FREE daily email newsletter.